Chimeron Bio Enters Into an Agreement With the NIAID, a Federal Agency, for Pre-clinical Assessment of Its Self-Amplifying COVID-19 Vaccine

Under the current agreement, Chimeron Bio will utilize the pre-clinical services program offered by the NIAID. Chimeron Bio will provide the vaccine candidate to test in the hamster model of COVID-19 which has previously been used for the assessment of other COVID-19 vaccines. “A successful outcome from this study will further validate ChaESAR™ technology in pre-clinical models and boost the design of a next generation single shot RNA vaccine that is durable, low dose, low cost, scalable and can render broad-spectrum protection against multiple variants or infectious agents,” said Thimmaiah Chendrimada, Co-founder and CSO of Chimeron Bio.

“We are grateful to receive NIAID’s support and work with NIAID funded world-class institutions. The COVID-19 program is Chimeron’s first foray into infectious diseases, and we expect the data from the current study to offer critical validation to advance CB-106 into non-human primates and demonstrate the applicability of ChaESAR™ technology for vaccines at large,” said Jolly Mazumdar, Co-founder and CEO of Chimeron Bio.

About Chimeron Bio
Chimeron Bio is a biotechnology company focused on the development of self-amplifying RNA (saRNA) therapeutics and vaccines across therapeutic areas. The company is using its proprietary ChaESAR^TM platform to develop a pipeline of products in oncology, rare genetic disorders, and infectious diseases. For more information, visit www.chimeron.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220321005759/en/